[1] Siegel R, Naishadham D, Jemal A.Cancer statistics, 2012[J].CA Cancer J Clin, 2012, 62(1):10-29. [2] Tse G, Chow DS, Hsu M, et al.Multidetector computed tomographic features of oncocytic papillary renal cell carcinoma a new subtype[J].J Comput Assist Tomogr, 2010, 34(6):380-384. [3] 汤钊猷.现代肿瘤学[M].上海:复旦大学出版社, 2006:113. [4] Reni M, Cordio S, Milandri C, et al.Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomized controlled multicentre phase Ⅲ trial[J].Lancet Oncol, 2005, 6:369-376. [5] Kindler HL, Friberg G, Singh DA, et al.Phase Ⅱ trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer[J].J Clin Oncol, 2005, 23(31):8033-8040. [6] Mullaney T, Olausson K, Sharp L.The influence of a department’s psychosocial climate and treatment environment on cancer patients’ anxiety during radiotherapy[J].Eur J Oncol Nurs, 2016, 20(1):113-118. [7] Aoyama T, Murakawa M, Katayama Y.Impact of postoperative complications on survival and recurrence in pancreatic cancer[J].Anticancer Res, 2015, 35(4):2401-2409. [8] Illidge T, Johnson P.The emerging role of radioimmunotherapy in hematological malignancies[J].Br J Haematol, 2000, 108(4):679. |